Stefano del prato biography of martin

Stefano Del Prato is a give up work Professor of Endocrinology and Metastasis at the School of Remedy, University of Pisa and Essential of the Section of Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Currently he is combine Professor of Medicine at nobility Interdisciplinary Research Center “Health Science” of the Sant’Anna School be more or less Advanced Studies in Pisa. He label MD cum laude from grandeur University of Padova and undertook post-graduate specialisation in both Endocrinology and Internal Medicine.

Professor Del Prato’s research interests have always antique concerned with diabetes and, alter particular, the physiopathology and treatment of type 2 diabetes explode insulin resistance syndrome.

He is pure member of many societies settle down associations, including the European Society for the Study of Diabetes (EASD), the American Diabetes Society, and the International Diabetes Confederation.

He acts as referee make public all major journals and has served on the Editorial Logs for the Journal of Clinical Endocrinology and Metabolism, Diabetes Concern, and the Journal of Diabetes and Its Complications, Journal be useful to Endocrinological Investigation, and Diabetes & Vascular Disease Research.

Professor Del Prato has published over 531 stint in national and international diary and has been awarded a handful honours, including the Prize quite a lot of the Italian Society of Diabetology for outstanding scientific activity.

Having served as Pilot of the EASD from 2011-14, he became President from 2020-2022. He also served as Impresario of Italian Society of Diabetology (2012-14) and as Chairman lay out the European Foundation for excellence Study of Diabetes (2015-19) bear is currently president of distinction European Diabetes Forum.

Duality of Interest: Professor Del Prato has established research support/grants from Astra Zeneca and Boehringer Ingelheim and speaker’s fees/honoraria from Astra Zeneca, Songster Chemie, Boehringer Ingelheim, Eli Lilly and Co, Menarini, Novo Nordisk and Sanofi.

He has also received payments for link of boards/advisory panels from Abbott, Amarin, Applied Therapeutics, Astra Zeneca, Bayer, Eli Lilly & Front, Hengrui Pharmaceuticals, Novo Nordisk, Sanofi and Sun Pharmaceuticals together arrange a deal consultancy payments from Menarini.

Date: Take a nosedive 2023